The pharmacogenomics of warfarin has been investigated extensively in recent years, in an effort to explain the inter-individual variability in the clinical response to this widely used anticoagulant. These studies have consistently demonstrated that polymorphisms in CYP2C9 and VK0RC1 modulate the warfarin dose requirement in various populations. In addition, a polymorphism in CYP4F2 has been implicated in warfarin dose/response in patients of European descent. Several warfarin dosing algorithms incorporating polymorphisms in VK0RC1, CYP2C9 and, in some cases, CYP4F2 as covariates have been described [l]. The predictive power of these algorithms varies markedly across populations, in part owing to interethnic differences in the frequency of the relevant pharmacogenetic polymorphisms [2,3].
展开▼
